(MENAFN - ProactiveInvestors - Australia) Alchemia (ASX: ACL) has recruited its 390th patient, giving it the full patient quota for the Phase III clinical trial of its lead cancer drug, HA-Irinotecan.
This final stage study compares the safety and efficacy of Alchemia's proprietary technology in combination with standard chemotherapy drug irinotecan against irinotecan alone in metastatic colorectal cancer patients.
The double blind trial is being conducted in second and third line patients.
Encouragingly, patients on the trial are continuing treatment for longer than anticipated before their disease progresses, which would have ended the trial.
Alchemia now expects to end the trial early in 2014 rather than in the second half of 2013 when an anticipated 350 patients experience disease progression.
The primary objective of the HyACT technology is to enhance existing drugs used for cancer chemotherapy to develop a new generation of anti-cancer drugs which demonstrates better efficacy than existing drugs.